Does Methylene Blue Usage Decrease the Post-operative Complications in Surgical Treatment of Pilonidal Disease.

The Effect of Using Methylene Blue in surgical treatment of Pilonidal Disease on Wound Infection and Relapse: A Prospective Randomized Study

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613001285741

Enrollment

231

Registered

2013-11-20

Start date

2008-06-05

Completion date

2012-10-29

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of this study to examine the effect of methylene blue (MB)dying on surgical treatment of pilonidal disease on wound infection and recurrence. We also investigated effectiveness of this dye in the presence of risk factors like age, body mass index, sex, number of primary and secondary orifices).Toataly, 231 patients were analyzed (129 patients MB+ and 102 patients MB-). Using intraoperative methylene blue prevents post-operative infection significantly. Its effect on preventing recurrence after in one year follow-up semms beneficial but not statisticaly significant.

Interventions

The aim of this study is to examine the protective effect of using methylene blue dying of the pilonidal sinus intraoperatively in the treatment of pilonidal disease to see whether this method is effective to prevent recurrence in 1 year follow-up and early post opertive surgical site infection and wound dehisence. 20-50 mL of methylene blue ( according to the volume of the pilonidal sinus) was applied through the greatest orfice of the sinus (subcutenous)

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

16 Years to 56 Years

Healthy volunteers

Inclusion criteria

Presence of pilonidal disease, patients treated with surgery, age >16

Exclusion criteria

Presence of any anal, perianal, and pilonidal infection or abscess, age <16, patients with immune depression or critically ill

Outcome results